Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Personalized Risk Stratification Model of Follicular Lymphoma Patients
A personalized risk stratification model for patients with Follicular Lymphoma is being studied. The trial NCT03436602 is currently active b…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Emapalumab Prevention of CAR-T Cell Associated Toxicities [Phase 2]
A Phase 2 clinical trial update evaluating emapalumab for preventing CAR-T cell–related toxicities in patients with relapsed or refractory B…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating CTX112 in relapsed or refractory B-cell malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
This document provides an update on a Phase 1 clinical trial evaluating the combination of lenalidomide and ibrutinib in patients with relap…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Long-term Follow-up Study of Patients Receiving CAR-T Cells
This clinical trial update outlines a long-term follow-up study of patients who received CAR-T cell therapy. Sponsored by the Medical Colleg…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 clinical trial evaluating the combination of Rituximab and Tafasitamab with allogeneic NK cells in relapsed/refractory B-cell non-Ho…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies [Phase 2]
This update reports a Phase 2 trial of loncastuximab tesirine for relapsed or refractory B-cell malignancies that is currently recruiting, i…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Q702 for the Treatment of Patients With Hematologic Malignancies [Phase 1]
This entry notes a Phase 1 clinical trial (Q702) for hematologic malignancies led by Mayo Clinic, currently recruiting and including histioc…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]
This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients w…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating epcoritamab in combination with standard platinum-based chemotherapy and autologous hematopoietic cell transplant…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update describes an ongoing Phase 1/2 study of selinexor in combination chemotherapy for advanced B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy [Phase 2]
A Phase 2 clinical trial evaluating odronextamab for relapsed or refractory diffuse large B-cell lymphoma before and after CAR T-cell therap…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin an…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial evaluates low-dose radiation as bridging therapy for relapsed or refractory B-cell non-Hodgkin lymphomas, including DLBCL…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL). [Phase 2]
Phase 2, multicenter, open-label trial evaluating subcutaneous mosunetuzumab in previously untreated low tumor burden follicular lymphoma.
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
This clinical trial update reports that recruitment is ongoing for a study evaluating zanubrutinib in patients with Waldenström's macroglobu…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma [EARLY_Phase 1]
This clinical trial update reports an early-phase study of a novel Bispecific AbTCR (anti-CD19/CD22) T-cell therapy for relapsed or refracto…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment [Phase 1]
Early-phase trial evaluating a three-drug combination (venetoclax, lenalidomide, and rituximab with hyaluronidase) in relapsed or refractory…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This clinical trial update describes a study assessing vaccine responses in patients who previously received CAR-T therapy for multiple myel…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas [Phase 1]
This entry provides an update on an ongoing Phase 1 trial of CD19-targeted CAR T-cells (CD19.20.22) for relapsed/refractory B-cell lymphomas…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial update evaluating the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refrac…
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 clinical trial update describes modified CD19/CD20 CAR-T cells for recurrent or refractory B-cell lymphoma or chronic lymphocytic …
-
CLINICAL_TRIALS research · 2025-09-03Clinical Trial Update: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma [Phase 3]
It reports an ongoing Phase 3 trial comparing shortened versus standard chemotherapy combined with immunotherapy as initial treatment for hi…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma [Phase 1]
An early-phase study at Memorial Sloan Kettering Cancer Center is evaluating measurements of cell-free DNA (cfDNA) in people with follicular…
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma [NA]
A clinical trial update describes a fixed-duration regimen of zanubrutinib, bendamustine, and obinutuzumab (ZBG) as first-line therapy for t…